517P - The implementation of a multidisciplinary heredofamilial cancer unit changes hereditary cancer risk perception among oncologists

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Familial Cancer
Presenter Iván Márquez-Rodas
Authors I. Márquez-Rodas1, A.B. Ruperez Blanco1, B. Moya1, S. Custodio Cabello1, S. Pérez Ramírez1, M. Cavanagh1, D. Lopez-Trabada1, S. López-Tarruella1, Y. Jerez1, M. Martin Jimenez2
  • 1Medical Oncology, Instituto Investigación Sanitaria Hospital Gregorio Marañón, 28007 - Madrid/ES
  • 2Instituto Investigación Sanitaria Hospital Gregorio Marañón, 28007 - Madrid/ES



A detailed family history and knowing the criteria for hereditary cancer risk are essential for oncology practice, since patients and relatives at risk could benefit from further genetic counseling (GC). The objective of this work is to compare the family history record and the hereditary cancer perception risk according to National Cancer Institute (NCI) criteria before and after the creation of a multidisciplinary heredofamilial cancer unit (HFCU) in our medical oncology service.

Table: 517P

Family history recorded (YES/NO) 172/616 (27.9%) 161/312 (51.6%) <0.01
NCI criteria (YES/NO) 104/616 (16.8%) 69/312 (22.1%) N.S
% GC referral 14/104 (13.5%) 31/69 (45%) <0.01
• Individual: 7/70 (10%) • Individual: 7/37 (18.9%)
GC referral and type of NCI criteria • Familial: 2/26 (8%) • Familial: 13/18 (72%) N.A.
• Both: 5/10 (50%) • Both: 11/14 (78,5%)


We retrospectively analyze the clinical records from new incoming patients of our medical oncology service in two cohorts: Cohort 1, from January 2009 to December 2009 (616 patients, before HFCU creation); and cohort 2, from May 2010 to April 2011 (after HFCU creation, first 312 patients analyzed). Family history record (yes/no) and NCI general hereditary cancer criteria (unusually early age; one or more first-degree relatives affected with the same or a related tumor; synchronous, bilateral or metachronous cancer in the same patient; atypical presentations) were collected. Results were compared using chi- square test. p <0.05 was considered significant.


The table summarizes the results. In cohort 1, 27.9% (172/616) of clinical records contained the family history, while in cohort 2 this percentage increased to 51.6% (116/312), (p < 0.01). 104/616 (16.8%) patients in cohort 1 and 69/312 (22.1%) in cohort 2, met NCI risk criteria (N.S.) In cohort 1, 13.5% (14/104) of these patients were referred to GC, while in cohort 2 this percentage increased to 45% (31/69) (p < 0.01).


The creation of a HFCU significantly increased the quality of family history records and the referral of patients at risk to GC. However, further efforts must be made in order to remark the importance of family history in oncology.


All authors have declared no conflicts of interest.